- 全部删除
您的购物车当前为空
Valziflocept (BAX1810; TAK-752)是一种靶向Fc和FcγR的重组可溶性人FcγRIIb受体。该受体通过结合并中和致病IgG发挥作用,充当“诱饵”或“清道夫”,从而有助于缓解自身免疫性疾病如系统性红斑狼疮(SLE)的病情。
Valziflocept (BAX1810; TAK-752)是一种靶向Fc和FcγR的重组可溶性人FcγRIIb受体。该受体通过结合并中和致病IgG发挥作用,充当“诱饵”或“清道夫”,从而有助于缓解自身免疫性疾病如系统性红斑狼疮(SLE)的病情。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | 待询 | 待询 | |
| 5 mg | 待询 | 待询 |
| 产品描述 | Valziflocept (BAX1810; TAK-752) is a recombinant soluble human FcγRIIb receptor designed to act as a "decoy" or "scavenger" by targeting Fc and FcγR, binding and neutralizing pathogenic IgG. Its utility lies in mitigating the impact of autoimmune diseases, making it a focus in systemic lupus erythematosus (SLE) research [1]. |
| 别名 | TAK-752, BAX1810 |
| CAS No. | 1804910-11-9 |
| 存储 | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
评论内容